Home Multimedia Podcasts TAKING THE RISK OUT OF CLINICAL DEVELOPMENT TAKING THE RISK OUT OF CLINICAL DEVELOPMENT August 30, 2007 – GEN’s Editor-in-Chief John Sterling interviews Kenneth Carter, Ph.D., President and CEO, Avalon Pharmaceuticals /wp-content/uploads/2018/09/gc133_8_30_2007.mp3 PodcastsResourcesClinical developmentDrug development (Pharmacology)Drug research and developmentGeneticsGenomicsOMICSPharmacologyResearch and developmentResearch resources Also of Interest Machines Bring Efficiency…and Empathy? Eric Topol Talks AI in Precision Medicine Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline Process Developers Encouraged to Consider Shipping from the Start GTC 2024: Nvidia’s Quantum Expansion Runs through the Cloud GTC 2024: Nvidia Highlights AI ‘Revolution’ in Drug Discovery, Genomics Related Media Thanks DC: GEN Editors' Final Report from ASHG Genetics in DC: A Report from ASHG Space Race: 10x CEO Serge Saxonov Discusses Single Cell and Spatial Biology on “Close to the Edge” Excitement in Oakland: A Report from SynBioBeta Celebrating DNA Day: An Interview with Eric Green on "The State of Genomics" Celebrating DNA: Matthew Cobb's Reflections on the Double Helix Related Content Machines Bring Efficiency…and Empathy? Eric Topol Talks AI in Precision Medicine Rising from the Ashes: FDA Grants EUA to Invivyd COVID-19 Antibody Novo Nordisk to Acquire Cardior for Up to $1.1B, Boosting Cardiovascular Pipeline Process Developers Encouraged to Consider Shipping from the Start